HYLORIS PHARMACEUTICALS SA
Company profile
Hyloris Pharmaceuticals SA specializes in the development and reformulation of existing pharmaceutical products, with a focus on cardiovascular diseases.
The company has 2 early stage commercial products : Sotalol IV for the treatment of atrial fibrillation developed in partnership with AltaThera (of which the commercialization in the United States is expected for Q3 2020), and Maxigesic® IV for the treatment of pain co-owned with AFT Pharmaceuticals (of which a number of approvals by European regulatory authorities are expected throughout H2 2020, and the approval by the U.S. FDA is expected for H2 2021, with commercialization in such jurisdictions expected after such approvals). Hyloris Pharmaceuticals SA also operates a portfolio of 12 products (of which 4 are in the cardiovascular space) in various stages of development.
Source: Cofisem - Last Update: 31 Aug 2020
Key figures
| Millenium | 2019 | 2018 | 2017 | ||
|---|---|---|---|---|---|
| Net sales | 91 | 91 | 213 | ||
| Income from ordinary activities | 91 | 91 | 213 | ||
| Operating income | -5,274 | -5,469 | -3,866 | ||
| Cost of financial indebtedness net | -415 | -339 | -146 | ||
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | -5,768 | -6,038 | -3,717 | ||
| Net income (Group share) | -5,373 | -5,791 | -3,717 | ||
| Fiscal year end | 12.19 | 12.18 | 12.17 | ||
| Length of fiscal year (month) | 12 | 12 | 12 | ||
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | ||
| Account Standards | |||||
| Source: Cofisem - Last Update: 31 Aug 2020 | |||||